- $352.54m
- $363.38m
Brief: Cytodyn To Offer No-Cost Testing For Childhood Inflammatory Disease Associated With Covid-19
Brief: Cytodyn Says 49 COVID-19 Patients Have Enrolled For Treatment With Leronlimab Through eIND
Brief: Cytodyn Announced Updates On 49 COVID-19 Patients Who Have Received Leronlimab Under FDA Program
Brief: Cytodyn’S Phase 2 Basket Trial For 22 Solid Cancer Tumors Treats First Patient With Leronlimab Patient Enrollment Delayed Due To Covid-19
Brief: Cytodyn Appoints Scott A. Kelly As Chief Medical Officer And Head Of Business Development
Brief: Cytodyn Says Patient With Covid-19 Exhibited Clinical Improvement After Treatment With Co's Investigational New Drug, Leronlimab
Brief: Novant Health Initiates Phase 2 Covid-19 Trial With Cytodyn’S Leronlimab
Brief: Cytodyn Collaborating With U.K.'s Dept Of Health To Provide Emergency Access To Leronlimab For Severe And Critically Ill Covid-19 Patients
Brief: Cytodyn Says 1st 2 Patients Enrolled In Randomized Phase 2, Covid-19 Trial With Leronlimab
Brief: Treatment With Cytodyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration In Severely Ill Covid-19 Patients
Brief: Cytodyn Files Trial Protocol With FDA To Treat COVID-19 Patients With Leronlimab
Brief: FDA Clears Cytodyn's Phase 2 Randomized Trial To Treat Mild-To-Moderately Ill Coronavirus Patients
Brief: Cytodyn Inc - New 3 Critically Ill COVID-19 Patients Treated With Leronlimab
Brief: Cytodyn Inc Says Two Additional Coronavirus Patients Treated With Co's Investigational New Drug, Leronlimab
Brief: Cytodyn - FDA Grants Emergency Ind For Two Coronavirus Patients Treated In New York With Cytodyn’S Leronlimab
Brief: Cytodyn Inc Files Modified IND And Protocol For Phase 2 Clinical Trial For Treatment Of Patients With Coronavirus With Leronlimab (Pro 140)
Brief: Cytodyn Receives Institutional Review Board Approval To Initiate Phase 2 Basket Trial For 22 Solid Tumor Cancers
Brief: Cytodyn Announced Continued Positive Data For Its Mtnbc And Mbc Patients
Brief: Cytodyn Signs Letter Of Intent For The Joint Development And Licensing Of Leronlimab In China With Longen China Group